Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Applications of epicatechin in preparation of drugs for preventing or treating myocardial fibrosis

A technique for myocardial fibrosis and epicatechin, which is applied in the directions of drug combination, pharmaceutical formula, cardiovascular system diseases, etc., can solve the problem that the therapeutic effect of epicatechin on myocardial fibrosis has not been reported yet.

Pending Publication Date: 2021-03-26
HARBIN MEDICAL UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the prior art research mainly focuses on the intervention effect of epicatechin on inflammation and oxidative stress-induced cardiovascular diseases, and there is no report on the therapeutic effect of epicatechin on myocardial fibrosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of epicatechin in preparation of drugs for preventing or treating myocardial fibrosis
  • Applications of epicatechin in preparation of drugs for preventing or treating myocardial fibrosis
  • Applications of epicatechin in preparation of drugs for preventing or treating myocardial fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] In this example, a TAC mouse model was established, and the improvement effect of epicatechin (EPI) on mouse heart function was investigated by means of ultrasound imaging, histopathology, microscopic observation and collagen deposition.

[0050] The concrete experimental method of this embodiment is:

[0051] Mice were fed ad libitum diet for 7 days under normal room temperature and humidity conditions. Mice were anesthetized with tribromoethanol (20 mg / kg, MCE, USA). Then the mice were randomly divided into control group, aortic arch stenosis (TAC) group, epicatechin group and TAC+epicatechin group, epicatechin group and TAC+epicatechin treatment group were given EPI 1mg by intragastric administration / kg body weight · day, continuous gavage for 28 days.

[0052] (1) After TAC or 28 days of treatment, echocardiography (visualonic Vevo 1100, Canada) was used to monitor the cardiac function of the mice in each group, and the monitoring results were as follows: figure...

Embodiment 2

[0064] This example investigated whether EPI can protect cardiac fibroblasts (CFs) from AngII-induced transformation of cardiac fibroblasts through in vitro experiments.

[0065] In this embodiment, primary cultured neonatal rat cardiac fibroblasts are used as an in vitro myocardial fibrosis model, and the specific experimental methods are as follows:

[0066] Rat neonatal suckling mice (1-2d) under aseptic conditions, open the chest and take out the heart, rinse with D-Hanks solution 3 times and cut into about 1mm 3 Add 2ml of trypsin (1g / L) to digest the cells in a 37°C water bath for 2-3min, and transfer the trypsin solution containing the cells to DMEM medium containing 10% fetal bovine serum. Repeat the above operations until the color of the myocardial tissue block becomes transparent. According to the difference in the attachment speed between cardiomyocytes and fibroblasts, the method of differential attachment was used to distinguish and obtain myocardial fibroblasts...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to applications of epicatechin in preparation of drugs for preventing or treating myocardial fibrosis, and belongs to the technical field of crude drugs. In order to provide a novel application of the epicatechin, the applications of the epicatechin in preparation of the drugs for preventing or treating myocardial fibrosis is disclosed. The using amount of the epicatechin is0.001-15 mg / Kg (weight / day). The drugs contain effective amount of epicatechin and pharmaceutically acceptable carriers and / or excipient. Through the verification of mouse experiments, the epicatechincan improve the cardiac functions of mice, protect mouse heart structures and relieve AngII induced myofibroblast transformation and collagen synthesis, so that the epicatechin is shown to have the effects of inhibiting myocardial fibrosis and has great application prospects on preventing and treating the myocardial fibrosis; and based on this, the novel applications of the epicatechin in preparation of the drugs for preventing or treating myocardial fibrosis is firstly provided.

Description

technical field [0001] The invention belongs to the technical field of natural medicines, and in particular relates to the application of epicatechin in the preparation of medicines for preventing or treating myocardial fibrosis. Background technique [0002] Myocardial fibrosis (MF) refers to a disease in the normal tissue structure of the myocardium, mainly manifested by cell proliferation and excessive deposition of extracellular matrix. Cardiac fibroblasts (Cardiacfibroblasts, CFs) abnormally proliferate and secrete a large amount of collagen in myocardial fibrosis, leading to pathological accumulation of extracellular matrix. A large number of studies in recent years have shown that myocardial fibrosis is closely related to many heart diseases, such as atrial fibrillation, myocardial infarction, chronic heart failure, and rheumatic heart valves. MF is a common pathological change in the development of various heart diseases to a certain stage, and it is also the key ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/353A61P9/00A61P9/04
CPCA61K31/353A61P9/00A61P9/04
Inventor 董增祥郭媛媛尹德春罗迎春汪增陆静
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com